Status:
COMPLETED
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Lead Sponsor:
Incuron
Conditions:
Solid Tumors
Glioblastoma
Eligibility:
All Genders
15+ years
Phase:
PHASE1
Brief Summary
This is an open-label, multi-center, sequential groups, dose-escalation study of CBL0137 administered intravenously in participants with metastatic or unresectable advanced solid malignancies.
Detailed Description
The primary objective of the study is to determine the maximally tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of CBL0137. The secondary objectives are to describe the dose-limiting toxicit...
Eligibility Criteria
Inclusion
- Patients must have histological or cytological evidence of a solid neoplasm
- Patients enrolled in the expansion cohort must have at least one measureable lesion as defined by the RECIST 1.1 criteria for patients with systemic tumors or the RANO criteria for patients with gliomas;
- Patients with a systemic tumor must:
- have metastatic or unresectable advanced solid tumors that have recurred or progressed following standard therapy or
- no longer be candidates for standard therapy or
- have tumors for which there is no standard therapy
- Patients with a glioma must:
- have Grade III (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma) disease, Grade IV (glioblastoma) disease, or diffuse intrinsic pontine glioma (DIPG) and;
- have received prior therapy including radiation and drug therapy and;
- have documented recurrent disease as defined in the RANO criteria;
- Patients must be ambulatory and have an ECOG Performance Score of 0 or 1;
- Patients or their legal representative must be able to provide written informed consent;
- Patients must have adequate bone marrow reserve as evidenced by:
- White Blood Cell Count (WBC) \> 3,000/µL
- Absolute Neutrophil Count (ANC) \> 1,500/µL
- Platelet count (PLT) \> 75,000/µL
- Hemoglobin (HGB) \> 8.0 gm/dL (patients may be transfused to achieve this HGB level);
- Patients must have adequate hepatic function as evidenced by:
- Serum AST/ALT \< 3X the upper limit of normal (ULN) for the reference lab (\< 5X the ULN for patients with known hepatic metastases)
- Serum bilirubin \< 1.5 x the ULN for the reference lab;
Exclusion
- Patients with active infection or with a fever \> 38.50 C within 3 days of the first scheduled day of dosing;
- Patients with symptomatic CNS metastases who have not undergone surgery and/or radiotherapy and/or who are not neurologically stable;
- Patients with known hypersensitivity to any of the components of CBL0137;
- Patients who are receiving concurrent anticancer therapy;
- Patients receiving enzyme-inducing antiepileptic agents within 14 days prior to the start of study therapy;
- Males with mean QTcF values of \> 450 msec and females with QTcF values of \> 470 msec following 3 ECGs conducted 5 minutes apart from each other; patients who are known to have congenital prolonged QT syndromes; or patients who are on medications known to cause prolonged QT intervals on ECG;
- Please speak with the PI for the complete Inclusion/Exclusion listing.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2019
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT01905228
Start Date
July 1 2013
End Date
June 1 2019
Last Update
December 10 2020
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
2
University Hospital of Cleveland
Cleveland, Ohio, United States, 44106
3
Cleveland Clinic
Cleveland, Ohio, United States, 44195
4
CTRC at The University of Texas Healh Science Center at San Antonio
San Antonio, Texas, United States, 78229